Sofinnova Partners closed Capital XI at €650 million (about US$750 million), exceeding its target to back early‑stage biopharma and medtech companies. The firm said the fund will lengthen its support through multiple financing rounds and prioritize therapeutics with strong translational potential. Sofinnova highlighted active investments across Europe and North America and emphasized operational support beyond capital. The close underscores renewed LP appetite for life‑sciences venture vehicles and provides fresh dry powder for companies approaching IND and early clinical inflection points.